http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-102921007-B
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_81d6af637871c95f327e1ea7d2593047 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-57 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P5-50 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-10 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-17 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-68 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K48-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-68 |
| filingDate | 2012-08-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2014-12-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f8185c7accc99e63e7dae7b566a202c2 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_72cd38dee50e34a7285d09659002dc08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_da67fee9b081e7929326a7e7472873ac |
| publicationDate | 2014-12-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-102921007-B |
| titleOfInvention | Method and reagent used for controlling insulin resistance and diabetes mellitus |
| abstract | The invention relates to a method and a reagent used for controlling insulin resistance and diabetes mellitus. According to the invention, substantial increasing of contents of amyloid protein or protein fragments in insulin resistance or diabetes mellitus patient peripheral blood is verified for a first time, and a novel approach is provided for the diagnoses of insulin resistance and type 2 diabetes mellitus. Also, for the first time, the invention discloses that amyloid prote beta (Abeta) can induce peripheral tissues to generate insulin resistance, wherein the induction is realized through activation of a JAK2/STAT3-SOCS-1 signaling pathway. Therefore, JAK2/STAT3-SOCS-1 signaling pathway or pathway proteins thereof can be adopted as target points for screening medicines, and medicines for controlling or relieving insulin resistance or diabetes mellitus can be studied. |
| priorityDate | 2011-08-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 490.